The maturation inhibitors are a class of antiviral drugs for the treatment of infection with HIV. They act by interfering with the maturation of the virus. Specifically, drugs in this class disrupt the final step in the processing of the HIV-1 gag protein, the cleavage of its immediate precursor by the enzyme HIV-1 protease. Unlike the class of drugs known as protease inhibitors, maturation inhibitors bind the gag protein, not the protease. This leads to the formation of noninfectious, immature virus particles, incapable of infecting other cells. No other class of drugs shares this mechanism of action, thus maturation inhibitors retain inhibitory activity against HIV infections with resistance.[1][2][3][4]
There are no currently available drugs from the class; however several clinical trials have been conducted. The first maturation inhibitor to be studied in humans was bevirimat,[5] another was MPC-9055 (vivecon).[6] Both were developed by Myriad Genetics, which has discontinued the maturation inhibitor program in 2010.[7] Others in development include BMS-2838232.
Referencesedit
^Salzwedel K, Martin DE, Sakalian M (2007). . AIDS Rev. 9 (3): 162–72. PMID 17982941. Archived from the original on 2016-08-03. Retrieved 2009-02-21.
^Adamson CS, Salzwedel K, Freed EO (August 2009). "Virus maturation as a new HIV-1 therapeutic target". Expert Opin. Ther. Targets. 13 (8): 895–908. doi:10.1517/14728220903039714. PMC2737327. PMID 19534569.
^Waheed AA, Freed EO (January 2012). "HIV type 1 gag as a target for antiviral therapy". AIDS Res. Hum. Retroviruses. 28 (1): 54–75. doi:10.1089/AID.2011.0230. PMC3251841. PMID 21848364.
^Jiang Y, Liu X, de Clercq E (2011). "New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle". Curr. Med. Chem. 18 (1): 16–28. doi:10.2174/092986711793979751. PMID 21110817.
^Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE (2007). "Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice". PLOS ONE. 2 (11): e1251. Bibcode:2007PLoSO...2.1251S. doi:10.1371/journal.pone.0001251. PMC2080775. PMID 18043758.
^"New HIV maturation inhibitor MPC-9055". National AIDS Treatment Advocacy Project. 17 September 2008. Retrieved 10 June 2012.
^. AIDSmeds. 8 June 2012. Archived from the original on 8 September 2015. Retrieved 27 June 2012.
maturation, inhibitor, maturation, inhibitors, class, antiviral, drugs, treatment, infection, with, they, interfering, with, maturation, virus, specifically, drugs, this, class, disrupt, final, step, processing, protein, cleavage, immediate, precursor, enzyme,. The maturation inhibitors are a class of antiviral drugs for the treatment of infection with HIV They act by interfering with the maturation of the virus Specifically drugs in this class disrupt the final step in the processing of the HIV 1 gag protein the cleavage of its immediate precursor by the enzyme HIV 1 protease Unlike the class of drugs known as protease inhibitors maturation inhibitors bind the gag protein not the protease This leads to the formation of noninfectious immature virus particles incapable of infecting other cells No other class of drugs shares this mechanism of action thus maturation inhibitors retain inhibitory activity against HIV infections with resistance 1 2 3 4 There are no currently available drugs from the class however several clinical trials have been conducted The first maturation inhibitor to be studied in humans was bevirimat 5 another was MPC 9055 vivecon 6 Both were developed by Myriad Genetics which has discontinued the maturation inhibitor program in 2010 7 Others in development include BMS 2838232 References edit Salzwedel K Martin DE Sakalian M 2007 Maturation inhibitors a new therapeutic class targets the virus structure AIDS Rev 9 3 162 72 PMID 17982941 Archived from the original on 2016 08 03 Retrieved 2009 02 21 Adamson CS Salzwedel K Freed EO August 2009 Virus maturation as a new HIV 1 therapeutic target Expert Opin Ther Targets 13 8 895 908 doi 10 1517 14728220903039714 PMC 2737327 PMID 19534569 Waheed AA Freed EO January 2012 HIV type 1 gag as a target for antiviral therapy AIDS Res Hum Retroviruses 28 1 54 75 doi 10 1089 AID 2011 0230 PMC 3251841 PMID 21848364 Jiang Y Liu X de Clercq E 2011 New therapeutic approaches targeted at the late stages of the HIV 1 replication cycle Curr Med Chem 18 1 16 28 doi 10 2174 092986711793979751 PMID 21110817 Stoddart CA Joshi P Sloan B Bare JC Smith PC Allaway GP Wild CT Martin DE 2007 Potent activity of the HIV 1 maturation inhibitor bevirimat in SCID hu Thy Liv mice PLOS ONE 2 11 e1251 Bibcode 2007PLoSO 2 1251S doi 10 1371 journal pone 0001251 PMC 2080775 PMID 18043758 nbsp New HIV maturation inhibitor MPC 9055 National AIDS Treatment Advocacy Project 17 September 2008 Retrieved 10 June 2012 Myriad Genetics suspends its HIV Maturation Inhibitor Program AIDSmeds 8 June 2012 Archived from the original on 8 September 2015 Retrieved 27 June 2012 nbsp This antiinfective drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Maturation inhibitor amp oldid 1175944568, wikipedia, wiki, book, books, library,
